Solid Biosciences (SLDB) Gains from Sales and Divestitures (2018 - 2024)
Historic Gains from Sales and Divestitures for Solid Biosciences (SLDB) over the last 6 years, with Q3 2024 value amounting to $237315.0.
- Solid Biosciences' Gains from Sales and Divestitures changed N/A to $237315.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $237315.0, marking a year-over-year change of. This contributed to the annual value of $183951.0 for FY2023, which is N/A changed from last year.
- According to the latest figures from Q3 2024, Solid Biosciences' Gains from Sales and Divestitures is $237315.0.
- In the past 5 years, Solid Biosciences' Gains from Sales and Divestitures ranged from a high of $419193.0 in Q4 2021 and a low of $183951.0 during Q4 2023
- For the 4-year period, Solid Biosciences' Gains from Sales and Divestitures averaged around $295739.0, with its median value being $237315.0 (2024).
- Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first soared by 2055.07% in 2020, then surged by 281.9% in 2021.
- Quarter analysis of 4 years shows Solid Biosciences' Gains from Sales and Divestitures stood at $407700.0 in 2020, then rose by 2.82% to $419193.0 in 2021, then tumbled by 56.12% to $183951.0 in 2023, then increased by 29.01% to $237315.0 in 2024.
- Its Gains from Sales and Divestitures stands at $237315.0 for Q3 2024, versus $230536.0 for Q2 2024 and $183951.0 for Q4 2023.